Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases

Aim. To evaluate the role of polymorphisms in adrenoceptor beta 1 (ADRB1) (Arg389Gly, rs1801253) and angiotensin-converting enzyme (ACE) (I/D, rs4343) genes in assessing the effectiveness of β-blocker (carvedilol) and ACE inhibitor (enalapril) therapy in women with anthracycline-induced cardiotoxici...

Full description

Bibliographic Details
Main Authors:	E. V. Grakova, K. V. Kopeva, S. N. Shilov, E. N. Berezikova, A. A. Popova, M. N. Neupokoeva, E. T. Ratushnyak, V. V. Kalyuzhin, A. T. Teplyakov
Format:	Article
Language:	English
Published:	Siberian State Medical University (Tomsk) 2023-01-01
Series:	Бюллетень сибирской медицины
Subjects:	антрациклин-индуцированная кардиотоксичность сердечная недостаточность полиморфизмы генов β-адреноблокатор ингибитор ангиотензинпревращающего фермента
Online Access:	https://bulletin.ssmu.ru/jour/article/view/5020

Similar Items

POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
by: V. I. Chernov, et al.
Published: (2016-02-01)

RADIONUCLIDE METHODS IN THE DETECTION AND FORECAST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN BREAST CANCER PATIENTS
by: V. I. Chernov, et al.
Published: (2016-12-01)

The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

In the wake of the latest clinical guidelines - mineralocorticoid receptor antagonists in the treatment of chronic heart failure
by: I. V. Zhirov, et al.
Published: (2015-12-01)

An angiotensin-converting enzyme inhibitor in the combination treatment of rheumatoid arthritis
by: E. B. Komarova, et al.
Published: (2017-09-01)

ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION
by: N. A. Dzhaiani
Published: (2015-09-01)

Kombinirovannaya terapiya ingibitorom angiotenzinprevrashchayushchego fermenta i diuretikom
by: I E Chazova, et al.
Published: (2006-06-01)

Protivoishemicheskoe, antiaritmicheskoe i sosudistoe deystvie ingibitora angiotenzinprevrashchayushchego fermenta zofenoprila v eksperimente
by: E V Shlyakhto, et al.
Published: (2006-06-01)

EARLY MARKERS OF PROGRESSION OF HEART FAILURE AND APOPTOSIS: THEIR ROLE IN PREDICTING THE RISK OF ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION
by: A. T. Teplyakov, et al.
Published: (2016-03-01)

БЕЗОПАСНОСТЬ ИНГИБИТОРОВ АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА В РАННИЕ СРОКИ БЕРЕМЕННОСТИ
by: Ф. И. Белялов
Published: (2015-02-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN ACUTE MYOCARDIAL INFARCTION: WHEN TO START THERAPY AND WHICH DRUG TO USE?
by: S. Y. Martsevich, et al.
Published: (2015-12-01)

Dynamics of the main parameters of structure-functional condition of the left ventricle myocardium in usage of combination antihypertension therapy for postmenopausal women with different obesity patterns
by: V. V. Skibitsky, et al.
Published: (2016-04-01)

Pleiotropic ACE inhibitor effects: any benefits for sulfhydryl agents?
by: D. V. Preobrazhensky, et al.
Published: (2008-02-01)

Primenenie ingibitorov angiotenzinprevrashchayushchego fermenta v lechenii arterial'noy gipertonii
by: A S Galyavich
Published: (2006-06-01)

Cardiorenal syndrome in patients with heart failure as a stage of the cardiorenal continuum (part 2): prognosis, prevention and treatment
by: E. V. Reznik, et al.
Published: (2019-03-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

COMBINATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND CALCIUM CHANNEL BLOCKERS IN HYPERTENSIVE PATIENTS WITH HEART FAILURE AND PRESERVED SYSTOLIC FUNCTION: IS THERE A PLACE FOR AN INFORMED CHOICE?
by: I. V. Zhirov, et al.
Published: (2013-12-01)

A META-ANALYSIS REPORTING EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTSWITHOUT HEART FAILURE
by: G. Savarese, et al.
Published: (2015-09-01)

Polimorfizm gena angiotenzinprevrashchayushchego fermenta pri sakharnom diabete 1 tipa u detey Sibiri
by: E I Kondrat'eva, et al.
Published: (2001-12-01)

Morphological and biochemical markers of inflammatory reactions in a mucous membrane of bronchial tubes at the heavy form of a bronchial asthma and chronic obstructive disease of lungs
by: Ye. A. Gereng, et al.
Published: (2009-06-01)

Sudden cardiac death and antipsychotic medications: literature review
by: V. P. Volkov
Published: (2012-10-01)

DISTRIBUTION OF POLYMORPHISMS OF GENES OF STATINS METABOLISM AND TRANSPORT IN THE LIVER IN PATIENTS WITH CORONARY ARTERY DISEASE ETHNIC UZBEKS WITH SIMVASTATIN INTOLERANCE
by: A. B. Shek, et al.
Published: (2017-03-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

IZUChENIE PLEYOTROPNYKh EFFEKTOV V-ADRENOBLOKATOROV I INGIBITOROV APF NA KOSTNUYu TKAN'
by: I A SKRIPNIKOVA, et al.
Published: (2014-12-01)

Molecular genetic risk factors for ischemic stroke in patients with thoracoabdominal malignant tumors
by: A. A. Korolyova, et al.
Published: (2023-02-01)

Effektivnoe i bezopasnoe ispol'zovanie perindoprila v doze 8 mg v kachestve startovogo lecheniya bol'nykh arterial'noy gipertoniey v usloviyakh statsionara (po rezul'tatam issledovaniya DOMINANTA)
by: O D Ostroumova, et al.
Published: (2006-06-01)

Heart failure in cancer patients
by: A. F. Khalirakhmanov, et al.
Published: (2022-01-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD?
by: V. V. Lomivorotov, et al.
Published: (2018-07-01)

Restenosis pathophysiological mechanisms and genetic markers after percutaneous coronary interventions
by: Yu. A. Shuvalova, et al.
Published: (2007-10-01)

Nuclear imaging of chemotherapy-induced cardiotoxicity
by: A. A. Ansheles, et al.
Published: (2021-03-01)

Fixed-dose combination of perindopril and indapamide: perspectives in hypertensive patients with inadequately controlled blood pressure
by: I. E. Chazova, et al.
Published: (2007-02-01)

Controlled arterial hypertension and adverse event free survival rate in heart recipients
by: A. О. Shevchenko, et al.
Published: (2018-08-01)

Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District
by: M. S. Soboleva, et al.
Published: (2020-04-01)

Pharmacokinetics and pharmacodynamics of a β-adrenoblocker bisoprolol: from mechanisms of action to clinical features
by: O. D. Ostroumova, et al.
Published: (2011-06-01)

COMBINATION ANTIHYPERTENSIVE THERAPY: WHEN THE WHOLE IS GREATER THAN THE SUM OF ITS PARTS
by: E. O. Taratukhin, et al.
Published: (2013-06-01)

Four-year follow-up of a patient with mixed cardiomyopathy and an implanted cardiac contractility modulation device: a case report
by: T. M. Uskach, et al.
Published: (2021-09-01)

NON-ANTIBACTERIAL ALTERNATIVE MEASURES FOR THE TREATMENT OF URINARY TRACT INFECTION IN CHILDREN. PART 2**. SUPPRESSION OF THE CONSEQUENCES OF MICROBIAL INITIATION OF INFLAMMATION
by: V. I. Kirillov, et al.
Published: (2018-09-01)

PHARMACOTHERAPY IN PATIENTS WITH ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA IN THE ABSENCE OF RISK OF DISEASE PROGRESSION
by: A. A. Kamalov, et al.
Published: (2018-03-01)